Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.





(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1530) (Convertible Bonds Code: 40285)

THE UNAUDITED KEY FINANCIAL INFORMATION AND INDICATORS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.* FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2020

The board of directors (the "**Board**") of the Company is pleased to announce that Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.* (三生國健藥業(上海)股份有限公司) ("**Sunshine Guojian**"), a subsidiary of the Company whose shares are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688336), published its quarterly report (the "**Report**") for the nine months ended 30 September 2020 on 18 October 2020.

The Board would like to draw the attention of the shareholders and investors of the Company to the following unaudited key financial information and indicators of Sunshine Guojian for the nine months ended 30 September 2020, as extracted from the Report:

I. KEY ACCOUNTING DATA

| Key accounting data | For the current reporting period (from 1 January to 30 September 2020) | For the corresponding period last year | |
|---|--|--|---|
| Revenue Net profit attributable to shareholders | 586,069,181.43 | 754,779,950.80 | -22.35 |
| of Sunshine Guojian Net profit attributable to shareholders of Sunshine Guojian after deducting | -56,897,176.05 | 55,372,335.79 | -202.75 |
| non-recurring profit and loss Net cash flow generated from | -41,191,443.30 | 125,218,285.17 | -132.90 |
| operating activities | 16,719,961.38 | 377,389,909.80 | -95.57 |
| | As at 30 September 2020 | As at 31 December 2019 | Changes as at the end of current reporting period as compared to the end of last year (%) |
| Net assets attributable to shareholders | | | |

| Net assets attributable to snareholders | | | |
|---|------------------|------------------|-------|
| of Sunshine Guojian | 4,670,775,395.55 | 2,868,011,899.97 | 62.86 |
| Total assets | 5,071,553,105.40 | 3,320,000,402.42 | 52.76 |

Note: The above financial data is presented in RMB and any discrepancies in percentage ratios are due to rounding.

II. KEY FINANCIAL INDICATORS

| Key financial indicators | For the current reporting period (from 1 January to 30 September 2020) | For the corresponding period last year | Changes in current reporting period as compared to the corresponding period last year (%) |
|---|--|--|---|
| Basic earnings per share (RMB/share) | -0.10 | 0.11 | -190.91 |
| Diluted earnings per share (RMB/share) | -0.10 | 0.11 | -190.91 |
| Weighted average returns on net assets (%) | -1.70 | 1.67 | -3.37 |
| Proportion of research and development expenses to revenue (%) | 46.03 | 26.35 | 19.68 |

Note: The full text of the Report is published on the information disclosure page of the website of the Shanghai Stock Exchange (http://star.sse.com.cn/disclosure/listannouncement/)

Shareholders and investors are reminded that the financial information above was prepared in accordance with PRC accounting standards and an extract of the unaudited financial statements prepared by Sunshine Guojian. In case of any discrepancy between the Chinese version and the English version, the Chinese version shall prevail.

By Order of the Board **3SBio Inc. Dr. LOU Jing** *Chairman*

Shenyang, the PRC 18 October 2020

As at the date of this announcement, the directors of the Company are Dr. LOU Jing and Ms. SU Dongmei as executive directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Dr. WONG Lap Yan as independent non-executive directors.